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Objectives. Cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) play a critical role in cancer development. We
investigated iNOS and COX-2 expression in relation to clinical outcome in 78 International Federation of Gynecology and Obstetrics (FIGO)
stage III ovarian serous carcinoma with a low grade of differentiation (G3).
Methods. Disease-free interval and cause-specific survival rates (Kaplan–Meier method) were compared using the log rank test. A
multivariate analysis (Cox-proportional hazards models) was used to determine the independent effect of each variable on prognosis. Fisher’s
exact test was used to analyze the distribution of iNOS and COX-2 expression according to clinical complete response to chemotherapy and
to the presence of a brief disease-free interval (V12 months).
Results. Overall 60 and 125 months cause-specific survival rates were 32% and 11%, respectively. In univariate analysis, iNOS (P = 0.005
and P = 0.003, respectively), COX-2 (P = 0.002 and P = 0.007, respectively), residual disease after surgery (P = 0.017 and P = 0.032,
respectively), and FIGO stage (P = 0.008 and P = 0.025, respectively) were associated with survival and a disease-free interval. In
multivariate analysis (Cox proportional hazards models), the factors that were found to be significantly independent predictors of disease
relapse as well as survival were iNOS (P = 0.014 and P = 0.001, respectively), COX-2 expression (P = 0.007 and P = 0.029, respectively),
and FIGO stage (P = 0.026 and P = 0.05, respectively). iNOS and COX-2 expressions were correlated with a brief disease-free interval (P =
0.001) and clinical complete response to first-line chemotherapy (P = 0.038 and P = 0.033, respectively).
Conclusions. The evaluation of iNOS and COX-2 expression may give additional prognostic information concerning the clinical outcome
of patients with ovarian carcinoma and may encourage them to select more tailored therapies.
D 2004 Elsevier Inc. All rights reserved.Keywords: Cyclooxygenase-2; Inducible nitric oxide synthase; Ovarian carcinoma; Chemotherapy response; Prognosis
Introduction associated with low survival rates. In the majority of theInvasive ovarian cancer is the most common cause of
death from gynecological cancers in the Western world. In
particular, serous carcinoma, the most frequent malignant
ovarian tumor, is generally diagnosed at later stages and is0090-8258/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.ygyno.2003.12.023
Abbreviations: iNOS, inducible nitric oxide synthase; NO, nitric oxide;
COX-2, cyclooxygenase-2.
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E-mail address: gl.taddei@unifi.it (G.L. Taddei).cases, women with advanced ovarian cancer are treated with
surgery followed by adjuvant therapy. The patients with
unresectable disease were submitted to exploratory laparot-
omy with multiple biopsies and received three cycles of
chemotherapy before performing a cytoreductive surgery.
The current recommendations for chemotherapy are
based on sequential prospective randomized trials in ovarian
cancer. These trials were based on the analysis of earlier
results that platinum combinations were superior to non-
platinum-based chemotherapy [1,2]. Despite improvements
in median and overall survival with the earlier development
of the platinums and the more recent addition of taxanes to
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patients with advanced ovarian cancer will not achieve a
complete response to adjuvant therapy and long-term sur-
vival rates for patients with advanced epithelial ovarian
carcinoma remain low.
The identification of additional prognostic and predictive
factors would be very helpful to better tailor treatments for
patients with ovarian carcinoma. A multimodality approach
using a combination of cytoreductive surgery, chemothera-
py, and assessment of biochemical factors more strictly
related to individual tumor biology and intrinsic aggressive-
ness is the direction of the future and can improve the
treatment of patients with ovarian carcinoma.
The cyclooxygenase enzymes COX-1 and COX-2 are
responsible for the conversion of arachidonic acid to prosta-
glandins. Research over the last decade, primarily in studies
focused on colorectal cancer, has established that nonsteroi-
dal anti-inflammatory drugs are effective in both cancer
prevention and as adjuvant therapy in the treatment of
established tumors [3].
Experimental data show that colorectal cancer cell
growth is primarily through the inhibition of cyclooxyge-
nase-2 (COX-2), and also that selective COX-2 inhibitors
have potent antineoplastic effect in vivo in preclinical
models of several solid malignancies.
Nitric oxide (NO) that comes from L-arginine by the
inducible nitric oxide synthase enzyme (iNOS) is a mole-
cule involved in several biological activities, such as vaso-
dilatation, neurotransmission, and cellular immune system.
Stimulation of inducible nitric oxide synthase and release
of nitric oxide by tumor cells play a critical role in cancer
development; in fact, the inducible nitric oxide synthase
enzyme has been implicated in tumor angiogenesis and
colon cancer progression [4] and has been reported in
human gynecological cancer [5].
Experimental evidence indicates that nitric oxide medi-
ates diverse aspects of tumor biology, such as host’s
immune suppression accompanying tumor growth [6], and
is advantageous to tumor growth and metastasis [7–9].
In a recent study, Klimp et al. [10] showed that not only
malignant, but also borderline and benign ovarian tumors
can exhibit increased levels of COX-2 and iNOS expres-
sion. In their analysis, the correlation of COX-2 and iNOS
status with clinical outcome is lacking.
Nose et al. [11] have suggested that enhanced expression
of both COX-2 and iNOS may have important roles in the
processes underlying thyroid tumorigenesis.
In ovarian carcinoma, COX-2 positivity has been recent-
ly correlated with the clinicopathological outcome of
patients [12–14]; while to our knowledge, no data have
been reported to the present about the expression of iNOS
and its possible clinical significance in ovarian cancer.
The adaption of COX-2 and iNOS as prognostic factors
for survival may add information to the well-accepted
clinicopathological parameters and enhance research to-
wards more tailored therapies. Whether any additionalbenefit will result from the inclusion of selective COX-2
inhibitors and iNOS inhibitors in the therapeutic plan of
patients whose tumors express them is an interesting hy-
pothesis which needs to be explored.
Thus, the aim of the present study is to investigate the
possible correlations between iNOS and COX-2 expression
in primary untreated ovarian carcinoma and the clinical
outcome of patients to give additional data to modulate
therapeutic tools for the patient.Materials and methods
Case selection
The files of the Department of Human Pathology and
Oncology of the University of Florence were searched from
1985 to 1999 for the diagnosis of ovarian carcinoma. Out of
these 494 cases, we selected a very homogeneous series of
International Federation of Gynecology and Obstetrics
(FIGO) stage III ovarian serous carcinoma with low grade
of differentiation (G3). The specimens come from 78
patients, with a known follow-up, who had undergone
surgical and adjuvant therapy at the Department of Gyne-
cology, Perinatology and Reproductive Medicine of the
University of Florence.
The mean age of our patients was 58 years and the median
was 60 years (range: 33–79 years). The age of 40 women
(51%) was higher than 60. The patients underwent laparot-
omy for optimal debulking of the gross neoplastic masses
with abdominal hysterectomy, bilateral salpingo-oophorec-
tomy, appendectomy, and omentectomy with careful exam-
ination of all serosal surface and biopsies of any suspected
lesions. All the patients presented residual disease after
surgery: 50 women (64%) had minimal residual disease
(< 2 cm) and 28 (35%) had bulk residual disease (z2 cm)
on completion of the initial surgery before chemotherapy as
described by the surgeon or by the histological examinations.
All patients were staged retrospectively according to a
modified staging system of the International Federation of
Gynecology and Obstetrics (FIGO) for malignant surface
epithelial–stromal tumors. Ten cases were FIGO stage IIIA,
8 were IIIB, and 60 cases were FIGO stage IIIC [15].
A postoperative treatment was performed in all patients
independently of the presence of minimal residual disease or
bulk residual disease and consisted of combined chemother-
apy regimes with six cycles of cisplatin-based chemotherapy,
unless they showed disease progression during adjuvant
treatment.
Until 1995, chemotherapy was based on combined
regimens with cisplatin and cyclophosphamide. After
1995, the chemotherapeutic treatment was based on com-
bined regimens with carboplatin (AUC 5) and either taxol or
cyclophosphamide.
After completion of treatment, the patients were fol-
lowed-up with a pelvic examination, the measurement of
Fig. 2. Immunohistochemical positive staining of anti-COX-2 polyclonal
antibody of the cell membrane and cytoplasm.
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abdominal ultrasonography (every 3 months for 2 years,
afterwards every 6 months), computed tomography of the
pelvis and the abdomen (once a year).
The follow-up period for each patient was until death or
at least 5 years after surgery, the median follow up was 32
months, and the mean value was 47 months, with observed
values ranging between 3 and 204 months following surgery
and first-line adjuvant therapy.
We have evaluated the clinical response to first-line
chemotherapy treatment according to computed tomography
of the pelvis and the abdomen with WHO methods [16]:
complete response (CR), partial response (PR), stable dis-
ease (S), and progression (P).
A brief disease-free interval is defined as when recurrence
or metastasis comes no later than 12 months after surgery
[17,18]. A disease-free interval was defined as the interval
time from primary treatment to recurrence or metastasis.
Cause-specific survival was defined as the survival time
from primary treatment to death due to the disease.
Immunohistochemical staining
The specimens were obtained by surgical resection in all
cases and fixed in 10% formalin before being processed in
paraffin. Hematoxylin–eosin-stained sections from each his-
tological specimen were reviewed by two pathologists to
confirm the histological diagnosis. A representative section
for each case was selected for immunohistochemical analysis.
The immunohistochemical study was performed by the
streptavidin–biotin–peroxidase method (UltraVision kit,
LAB VISION; Fremont, CA) with diaminobenzidine
(DAB) as chromogen and Mayer’s hematoxylin as nuclear
counterstain with two different antibodies.
We studied the inducible nitric oxide synthase enzyme
with anti-iNOS polyclonal antibody (Biomol Laboratories,
Plymouty, PA; 1:600 dilution for 5 h, at 4jC), with biotiny-Fig. 1. Immunohistochemical positive staining of anti-iNOS polyclonal
antibody of the cell membrane and cytoplasm.lated goat anti-polyvalent secondary antibody (UltraVision,
Lab Vision Corporation, Fremont, CA), and with antigen
rescue in the microwave with citrate buffer, pH 6 for 10V.
The second enzyme analyzed was cyclooxygenase-2
with goat polyclonal antibody anti-COX-2 (Santa Cruz
Biotechnology, Santa Cruz, CA; 1:50 dilution overnight,
at 4jC), with biotinylated rabbit anti-goat secondary anti-




Clinical responsiveness to chemotherapy
Complete response 55
Partial response 7
Progression after treatment 16
















Prognostic factors by univariate analysis (Cox proportional hazards model)
Variable Relapse Death
Score Hazard ratio 95% CI P Score Hazard ratio 95% CI P
iNOS 0 0
1 2.09 1.24–3.51 0.005 1 2.27 1.33–3.89 0.003
COX-2 0 0
1 2.41 1.37–4.23 0.002 1 2.19 1.24–3.87 0.007
Residual disease 0 0
1 1.82 1.11–2.98 0.017 1 1.73 1.04–2.87 0.032
FIGO stage
IIIA 0 0
IIIB 1 2.91 0.96–8.74 0.057 1 1.36 0.41–4.51 0.607
IIIC 2 3.16 1.34–7.41 0.008 2 2.69 1.13–6.42 0.025
Age z60 years 0 0
1 0.97 0.60–1.57 0.92 1 0.9 0.55–1.48 0.7
CI, confidence interval.
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buffer (Tris-EDTA-citrate), pH 8 for 20V.
Negative control was performed by substituting the
primary antibody with nonimmune sera. Appropriate posi-
tive and negative controls were run simultaneously.
The immunohistochemically stained sections were eval-
uated without previous knowledge of the clinical outcome
of each patient.
Evaluation of inducible nitric oxide synthase and
cyclooxygenase-2 expression
The tumor sections showing brown staining of the anti-
bodies specific iNOS and COX-2 of cytoplasm were scored
as positive. The proportion of immunostained cells was
scored at low magnification (5 objective lens) by evaluat-
ing the entire tumor area. When the tumor area with positive
immunostaining was >10% of the total tumor area, the case
was scored as positive. The intensity of staining was also
evaluated subjectively using a range from 0 (none) to 1
(feint) to 2 (strong). Cases in which the intensity of staining
was scored <2 were considered negative; as previously
described for cyclooxygenase-2 expression [12].Table 3
Significant prognostic factors by multivariate analysis (Cox proportional hazards
Variable Relapse D
Score Hazard ratio 95% CI P
iNOS 0
1 1.95 1.14–3.34 0
COX-2 0
1 2.19 1.23–3.88 0
Residual disease 0
1 1.56 0.92–2.66 0
FIGO stage
IIIA 0
IIIB 1 2.69 0.88–8.21 0
IIIC 2 2.71 1.12–6.51 0
CI, confidence interval.Statistical analyses
A disease-free interval and cause-specific survival rates
were calculated according to the Kaplan–Meier method
[19] and differences were evaluated using the log rank
test.
A univariate analysis, with Cox proportional hazards
models, was used to determine which variables had an effect
on clinical outcome. A P value V0.05 was considered to be
statistically significant. In the multivariate analysis, we had
analyzed the variables which in the univariate analysis had a
P statistically significant. A multivariate analysis (Cox pro-
portional hazards model) was used to determine which
variables had an independent effect on clinical outcome
[20]. A P value V0.05 was considered to be statistically
significant.
The optimized cut-out points were calculated as those
corresponding to the lowest values that by multivariate
analysis were significantly and independently associated
with both disease-free interval and cause-specific survival.
Fisher’s exact test was used to analyze the distribution of
iNOS and COX-2-positive cases according to clinical re-
sponse to chemotherapy and to the presence of recurrence ofmodel)
eath
Score Hazard ratio 95% CI P
0
.014 1 2.46 1.41–4.29 0.001
0
.007 1 1.9 1.06–3.4 0.029
0
.097 1 1.4 0.82–2.41 0.21
0
.082 1 1.01 0.3–3.36 0.98
.026 2 2.43 0.99–5.95 0.05
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treatment.
Data analysis was performed using the Statacorp.2001.
Stata Statistical Software: Release 7.0. College Station, TX:
Stata Corporation [21].Results
iNOS and COX-2 immunostaining
Intense iNOS immunostaining was observed in the
cytoplasm of tumor cells in 50 cases (64%), and high
staining intensity for COX-2 was observed in 54 cases
(69%). Figs. 1 and 2 show representative examples of an
ovarian carcinoma with intense iNOS and COX-2 immu-
nostaining, respectively. The tumor cells presented a posi-
tive immunostaining for both the two antibodies in 37 cases
(47%).Fig. 3. Probability of disease-free survival (a) and cause-specific survival
(b) according to the presence versus the absence of iNOS expression (P =
0.014 and P = 0.001, respectively).
Fig. 4. Probability of disease-free survival (a) and cause-specific survival
(b) according to the presence versus the absence of COX-2 expression (P =Correlation of iNOS and COX-2 expression with clinico-
pathologic parameters
Clinical characteristics and outcome of 78 patients with
serous ovarian carcinoma are shown in Table 1.
Fifty-five patients (70%) presented a complete clinical
response to first-line chemotherapy after surgical treatment,
evaluated according to the WHO methods [16]; seven
0.007 and P = 0.029, respectively).Table 4
iNOS and COX-2 expression in correlation with the disease-free interval







Positive 40 cases (80%) 10 cases (20%) 0.001
Negative 12 cases (42%) 16 cases (57%)
COX-2 expression
Positive 43 cases (79%) 11 cases (20%) 0.001
Negative 9 cases (37%) 15 cases (62%)
M.R. Raspollini et al. / Gynecologic Oncology 92 (2004) 806–812 811patients (8%) presented a partial response, and in 16 patients
(20%) the disease was in progression after surgery and
adjuvant treatment. None of the patients were with stable
disease.
The overall 60 and 125 months cause-specific survival
rates were 32% and 11%, respectively. Fifty-two patients
(66%) showed a brief disease-free interval, and 69 patients
(88%) showed recurrence of disease.
Using univariate analysis, several parameters, such as
iNOS (P = 0.005 and P = 0.003, respectively) and COX-2
expression (P = 0.002 and P = 0.007, respectively), the
residual disease after surgery (P = 0.017 and P = 0.032,
respectively), and the FIGO stage IIIC even more than FIGO
stage IIIA (P = 0.008 and P = 0.025, respectively), were
found significantly associated with the risk of recurrence or
metastases and death from disease (Table 2).
Using multivariate analysis (Cox proportional hazards
models), the only factors that were found to be significant
independent predictors of disease relapse as well as survival
were iNOS (P = 0.014 and P = 0.001, respectively) and
COX-2 expression (P = 0.007 and P = 0.029, respectively),
and FIGO stage IIIC even more than FIGO stage IIIA (P =
0.026 and P = 0.05, respectively) (Table 3).
Kaplan–Meier estimates of a disease-free interval and
cause-specific survival by iNOS and COX-2 expression are
shown in Figs. 3 and 4, respectively.
iNOS and COX-2 expressions are significantly correlated
with the disease-free interval of V12 months (Fisher’s exact
test, P = 0.001) (Table 4).
iNOS and COX-2 negative ovarian carcinomas are sig-
nificantly correlated with clinical complete response to first-
line chemotherapy. In fact, in 85% of the iNOS-negative
cases, the response to first-line chemotherapy was complete;
while 38% of the patients with iNOS-positive ovarian carci-
noma presented partial response or progression of the disease
after the first-line chemotherapy (Fisher’s exact test, P =
0.038). We can observe the same trend of poorer prognosis of
iNOS-positive cases also for COX-2-positive cases. In fact, in
87% of the COX-2 negative cases, the response to first-line
chemotherapy was complete, while 37% of the patients withTable 5
iNOS and COX-2 expression, respectively, in correlation with the clinical
complete response to chemotherapy versus clinical not complete response to











Positive 31 cases (62%) 19 cases (38%) 0.038
Negative 24 cases (85%) 4 cases (14%)
COX-2 expression
Positive 34 cases (62%) 20 cases (37%) 0.033
Negative 21 cases (87%) 3 cases (12%)COX-2-positive ovarian carcinoma presented partial re-
sponse or progression of disease after the first-line chemo-
therapy (Fisher’s exact test, P = 0.033) (Table 5).Discussion
To the best of our knowledge, a study designed to
determine the association between iNOS and COX-2 ex-
pression and reduced susceptibility to chemotherapy and
prognosis in a series of primary advanced untreated ovarian
serous carcinomas has never been performed.
Epidemiological data indicate that nonsteroidal anti-in-
flammatory drugs may be effective in the prevention of
ovarian cancers [22,23]. Preclinical evaluation of these drugs
as chemopreventive agents by Rodriguez-Burford et al. [24]
provides in vitro evidence of direct growth inhibitory effects
of these agents. In particular, the COX-2 inhibitors, across all
the cell lines tested, call for additional studies for the use of
nonsteroidal anti-inflammatory drugs in addition to the
adjuvant therapy in ovarian cancer; in particular, in the cases
that show COX-2 expression [25].
Recently, studies [12,13] have shown that increased
cyclooxygenase-2 expression is associated with chemother-
apy resistance and clinical outcome in a series of III and IV
FIGO stage ovarian cancer patients who had undergone
either primary debulking and subsequent chemotherapeutic
treatment or exploratory laparotomy and chemotherapy.
Denkert et al. [14] correlated COX-2 with the prognosis in
ovarian carcinoma of different stages and histopathologic
types and in low malignant potential ovarian tumors.
Our analysis consists of a series of III stage FIGO serous,
G3, ovarian carcinoma patients who had undergone surgical
treatment and following chemotherapy.
A preclinical study with regards to iNOS gene expression
in ovarian carcinoma cell lines following incubation with
different combinations of interferon-g, interleukin-1h, lipo-
polysaccharide, and tumor necrosis factor-a demonstrated
variations in nitric oxide production with interferon-g and
different patterns of nitric oxide release in response to in-
flammatory stimuli in ovarian carcinoma cell lines [26]. Saito
et al. [27] previously showed that interferon-g exerts anti-
proliferative effects on neoplastic cells, including ovarian
cancer. Intraperitoneal treatment with interferon-g has been
shown to achieve documented surgical responses in the se-
cond-line therapy of ovarian cancer and also in the first-line
[28].
Garman and Bonavida [29] demonstrated that induction
of apoptotic cell death in the ovarian carcinoma cell line
AD10 by interferon-g induced iNOS gene expression.
Rieder et al. [30] recently showed that nitric oxide pro-
duced by ovarian carcinomas is correlated to the intensity
of tumor cell death by apoptosis; thus, it is conceivable
that tumor cells generating large amounts of nitric oxide
are susceptible to nitric oxide-mediated killing cell. Also,
Kost et al. [31] found synergistic cytolytic effects of
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cell lines.
The data suggest the utility of additional studies to better
characterize the role of interferon-g in ovarian cancer
because it seems correlated with iNOS gene expression to
hypothesize additional therapeutic strategies in ovarian
cancer patients.
We detected iNOS and COX-2 expression in the majority
of the ovarian cancer samples tested; in particular, they
showed a correlation with clinical outcome. In our series of
cases that included only serous ovarian cancer with low
grade of differentiation, G3, FIGO stage III, which had
undergone the same surgical and adjuvant treatment, we
showed that iNOS and COX-2 immunohistochemical ex-
pression can give us prognostic information for clinical
outcome of the patient. In our cases, both iNOS and
COX-2 positivity are associated with a shorter survival
period, with a relapse or metastases of disease and also
with disease-free interval shorter than 12 months [17,18].
Moreover, our study proves that both iNOS and COX-2-
negative ovarian carcinomas are statistically correlated with
clinical complete response to first-line chemotherapy.
The above results indicate the necessity to further inves-
tigate the status of iNOS and COX-2 in ovarian cancer to
develop additional treatment options as more studies and
clinical trials are performed.References
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